M Verstraete - Concepedia

Author

M Verstraete

Also Known As

G Tognoni, M VERSTRAETE, M Verstraete, M. VERSTRAETE, M. Verstraete, Marc Verstraete, Marie Astrid Garcia Verstraete, Marvin Verstraete, Verstraete, Marvin

306

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

KU Leuven UCLouvain Universitair Ziekenhuis Leuven

About

M Verstraete is an author at KU Leuven specializing in medicine, thrombosis, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	47	7.1K
2	Public Health	10	10	1.1K
3	Health Sciences	4	4	205
4	Engineering	3	3	96
5	Natural Sciences	2	2	36

M Verstraete

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS Robert Altman, L Carreras, Rubén Sierra Díaz, Oxford University Research Archive (ORA) (University of Oxford) ThrombosisIschemic StrokeCardiovascular DiseaseMedicineBlood Platelet	1994	3.3K
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION M Verstraete, M Bory, D Collen, The Lancet ThrombosisCardiovascular DiseaseFibrinolysisCardiologyPharmacotherapy	1985	752
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. M Verstraete, Graham Miller, Henri Bounameaux, Circulation ThrombosisPulmonary EmbolismMg Rt-paVenous ThrombosisIntravenous Administration	1988	406
Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis. EFFECT OF MOLECULAR FORM AND DOSE OF ACTIVATOR, AGE OF THE THROMBUS, AND ROUTE OF ADMINISTRATION D Collen, Jean Marie Stassen, M Verstraete Journal of Clinical Investigation Percent ThrombolysisBiomedical EngineeringHuman ExtrinsicThrombosisVenous Thrombosis	1983	243
DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION M Verstraete, Ronald W. Brower, D Collen, The Lancet ThrombosisCardiovascular DiseaseAtherosclerosisCoronary Artery DiseaseMyocardial Infarction	1985	240
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration D Collen, John A. Schetz, F De Cock, European Journal of Clinical Investigation	1977	172
Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Jos L. Willems, Rik Willems, GM Willems, Circulation ThrombosisCardiovascular DiseaseThrombolytic TherapyAtherosclerosisCoronary Artery Disease	1990	165
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. M Verstraete, H Bounameaux, F De Cock, Journal of Pharmacology and Experimental Therapeutics	1985	155
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. D Collen, H Bounameaux, F De Cock, Circulation ImmunologyAcute Myocardial InfarctionIntravenous InfusionThrombosisHematology	1986	152
Dipyridamole Inhibits Platelet Aggregation in Whole Blood Paolo Gresele, Carla Zoja, Hans Deckmyn, Thrombosis and Haemostasis ThrombopoiesisThrombosisBlood PlateletMedicinePlatelet Aggregation	1983	144

Page 1